Corvus Pharmaceuticals (CRVS) Other financing activities (2015 - 2026)
Corvus Pharmaceuticals (CRVS) posted quarterly Other financing activities of $1.3 million for Q1 2026, up 379.93% year-over-year from $279000.0 in Q1 2025, and up 1876.38% quarter-over-quarter from $67750.0 in Q3 2025.
Powered by 
Analysis
Corvus Pharmaceuticals (CRVS) Other financing activities (2015 - 2026) Analysis & Trends
Corvus Pharmaceuticals' Other financing activities history runs 10 years deep, the most recent figure standing at $1.3 million for Q1 2026.
- In Q1 2026, Other financing activities rose 379.93% year-over-year to $1.3 million; the TTM figure through Mar 2026 stood at $3.4 million (up 171.81% YoY), while the FY2025 annual figure was $35.7 million, up 52466.18% from the prior year.
- Other financing activities for Q1 2026 stood at $1.3 million, up from $67750.0 in the prior quarter.
- The five-year high for Other financing activities was $3.9 million in Q3 2024, with the low at -$8.9 million in Q4 2024.
- The 4-year median for Other financing activities is $173375.0 (2025), against an average of -$163561.8.
- The sharpest annual moves came in 2024 and 2025: Other financing activities surged 48687.5% in 2024, then slumped 98.26% in 2025.
- Corvus Pharmaceuticals' Other financing activities stood at $8000.0 in 2023, then plunged by 110925.0% to -$8.9 million in 2024, then jumped by 100.76% to $67750.0 in 2025, then soared by 1876.38% to $1.3 million in 2026.
- Business Quant data shows CRVS's Other financing activities at $1.3 million in Q1 2026, $67750.0 in Q3 2025, and $2.0 million in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Corvus Pharmaceuticals | 1.33 Bn | 1.12 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 166,000.00 |
| Mar 31, 2026 | 1.34 Mn |
| Sep 30, 2025 | 2.94 Mn |
| Jun 30, 2025 | 54.30 Mn |
| Mar 31, 2025 | 279,000.00 |
| Dec 31, 2024 | 9.66 Mn |
| Sep 30, 2023 | 8,000.00 |
| Mar 31, 2023 | 4,000.00 |
| Dec 31, 2021 | 18,000.00 |
| Dec 31, 2020 | 1,000.00 |
| Sep 30, 2020 | 64,000.00 |
| Dec 31, 2019 | 2,000.00 |
| Sep 30, 2019 | 16,000.00 |
| Jun 30, 2019 | 5,000.00 |
| Mar 31, 2019 | 1,000.00 |
| Dec 31, 2018 | 172,000.00 |
| Sep 30, 2018 | 166,000.00 |
| Jun 30, 2018 | 48,000.00 |
| Mar 31, 2018 | 7,000.00 |
| Dec 31, 2017 | 597,000.00 |